INSULET CORP
Business
Insulet Corporation develops, manufactures, and sells proprietary continuous insulin delivery systems, primarily the Omnipod platform (Omnipod 5, Omnipod DASH, and Classic Omnipod), for people with insulin-dependent diabetes. The company also manufactures pods for Amgen's Neulasta Onpro kit. Omnipod products are tubeless, disposable, wearable devices that deliver insulin subcutaneously for up to three days and integrate with continuous glucose monitors and automated insulin delivery algorithms. Insulet distributes through wholesalers, distributors, and direct-to-consumer channels across multiple countries, with a substantial portion of sales through intermediaries.
Summary from 10-K filed 2026-02-18
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue | 2,708 | 2,072 | 1,697 | 1,305 | 1,099 | |
| Cost of revenue | 768 | 626 | 537 | 500 | 347 | |
| Gross profit | 1,940 | 1,446 | 1,160 | 806 | 752 | |
| Research and development expenses | 301 | 220 | 205 | 180 | 160 | |
| Selling, general and administrative expenses | 1,165 | 917 | 735 | 588 | 466 | |
| Operating income | 474 | 309 | 220 | 38 | 126 | |
| Interest expense, net of portion capitalized (Note 8) | −59 | −43 | −36 | −36 | — | |
| Interest income | 35 | 40 | 29 | 9 | 500,000 | |
| Loss on extinguishment of debt | −124 | 0 | 0 | 0 | −42 | |
| Other income (expense), net | 14 | −6 | 2 | −1 | −2 | |
| Income before income taxes | 340 | 300 | 215 | 10 | 21 | |
| Income tax (expense) benefit | −92 | 118 | −8 | −5 | −4 | |
| Net income | 247 | 418 | 206 | 5 | 17 | |
| Basic (in dollars per share) | 3.51 | 5.97 | 2.96 | 0.07 | 0.25 | |
| Diluted (in dollars per share) | 3.48 | 5.78 | 2.94 | 0.07 | 0.24 | |
| Basic (in shares) | 70 | 70 | 70 | 69 | 68 | |
| Diluted (in shares) | 72 | 74 | 74 | 70 | 69 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 716 | 953 | 704 | 675 | 792 | |
| Inventories | 453 | 430 | 403 | 347 | 303 | |
| Prepaid expenses and other current assets | 228 | 142 | 116 | 87 | 74 | |
| Total current assets | 1,914 | 1,891 | 1,583 | 1,314 | 1,330 | |
| Property, plant and equipment, net | 820 | 723 | 665 | 600 | — | |
| Other intangible assets, net | 117 | 99 | 99 | 76 | 37 | |
| Goodwill | 52 | 52 | 52 | 52 | 40 | |
| Deferred tax assets | 82 | 142 | 2 | — | — | |
| Other assets (includes $1.0 and $10.1 at fair value) | 206 | 182 | 188 | 210 | 106 | |
| Total assets | 3,190 | 3,088 | 2,588 | 2,251 | 2,049 | |
| Accounts payable | 75 | 20 | 19 | 31 | 38 | |
| Current portion of long-term debt | 18 | 84 | 49 | 28 | 25 | |
| Total current liabilities | 680 | 528 | 451 | 365 | 229 | |
| Long-term debt, net | 931 | 1,296 | 1,366 | 1,374 | — | |
| Other liabilities | 64 | 52 | 38 | 36 | 15 | |
| Total liabilities | 1,675 | 1,876 | 1,856 | 1,775 | 1,493 | |
| Commitments and contingencies (Note 16) | — | — | — | — | — | |
| Preferred stock, $.001 par value, 5,000,000 authorized; none issued and outstanding | 0 | 0 | 0 | 0 | 0 | |
| Common stock, $.001 par value, 100,000,000 authorized; 70,588,192 and 70,390,816 shares issued and outstanding, respectively, at December 31, 2025; and 70,196,031 issued and outstanding, at December 31, 2024 | 100,000 | 100,000 | 100,000 | 100,000 | 100,000 | |
| Additional paid-in capital | 1,275 | 1,184 | 1,103 | 1,041 | 1,208 | |
| Accumulated earnings (deficit) | 287 | 40 | −378 | −584 | −650 | |
| Accumulated other comprehensive income (loss) | 13 | −13 | 8 | 20 | −2 | |
| Treasury stock, at cost; 197,374 and shares | −60 | 0 | — | — | — | |
| Deferred compensation | 800,000 | 0 | — | — | — | |
| Total stockholders equity | 1,515 | 1,212 | 733 | 476 | 556 | |
| Total liabilities and stockholders equity | 3,190 | 3,088 | 2,588 | 2,251 | 2,049 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 90 | 81 | 73 | 63 | 57 | |
| Stock-based compensation expense | 63 | 69 | 48 | 41 | 34 | |
| Deferred income taxes | 62 | −137 | 500,000 | −1 | — | |
| Non-cash interest expense | 6 | 7 | 7 | 6 | 40 | |
| Gain on derivative asset | −13 | 0 | 0 | — | — | |
| Provisions for credit losses | 5 | −200,000 | 2 | — | — | |
| Loss (gain) on investments | 0 | 4 | −3 | — | — | |
| Other | 7 | 5 | 2 | 4 | 1 | |
| Inventories | −11 | −32 | −54 | −49 | −154 | |
| Prepaid expenses and other assets | −82 | −22 | −42 | −37 | −47 | |
| Accounts payable | 49 | 2 | −11 | −2 | −16 | |
| Net cash provided by operating activities | 569 | 430 | 146 | 119 | −68 | |
| Capital expenditures | −192 | −125 | −76 | −123 | −112 | |
| Investments in developed software | −19 | −9 | −9 | −13 | −11 | |
| Acquisition of other intangible assets | −9 | 0 | −25 | −22 | 0 | |
| Cash paid for investments | 0 | −12 | −7 | −8 | 0 | |
| Other | −3 | 0 | −3 | — | — | |
| Net cash used in investing activities | −223 | −146 | −119 | −191 | −83 | |
| Proceeds from issuance of senior unsecured notes, net of issuance costs | 441 | 0 | 0 | — | — | |
| Proceeds from issuance of Term Loan B, net of issuance costs | 16 | 130 | 0 | 0 | 490 | |
| Repayment of Term Loan B | −21 | −137 | −5 | −5 | −3 | |
| Repayment of equipment financings | −18 | −19 | −20 | −17 | −18 | |
| Repayment of Convertible Senior Notes | −1,052 | 0 | 0 | 0 | −461 | |
| Financing lease repayments | 0 | −23 | 0 | −15 | 0 | |
| Repayment of mortgage | −61 | −2 | −2 | −2 | −2 | |
| Proceeds from secured borrowing (Note 5) | 50 | 46 | 0 | 0 | — | |
| Repayment of secured borrowing (Note 5) | −62 | −35 | 0 | 0 | — | |
| Settlement of capped call options | 165 | 0 | 0 | — | — | |
| Repurchase of common stock | −60 | 0 | 0 | — | — | |
| Proceeds from exercise of stock options | 19 | 8 | 16 | 7 | 15 | |
| Proceeds from issuance of common stock under employee stock purchase plan | 15 | 12 | 11 | 9 | 8 | |
| Payment of withholding taxes in connection with vesting of restricted stock units | −26 | −8 | −13 | −17 | −28 | |
| Other | 0 | 0 | −300,000 | 0 | — | |
| Net cash used in financing activities | −595 | −28 | −14 | −40 | 41 | |
| Effect of exchange rate changes on cash and cash equivalents | 12 | −7 | 2 | −4 | −6 | |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | −237 | 249 | 14 | −117 | −116 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is INSULET CORP's CIK number?
INSULET CORP's SEC CIK number is 0001145197 (1145197). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find INSULET CORP's SEC filings?
All of INSULET CORP's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did INSULET CORP last report earnings?
INSULET CORP (PODD) most recently filed an earnings 8-K with the SEC on May 6, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001145197-26-000100). This is INSULET CORP's most recent earnings filing of record — not a forecast of its next earnings date.
What is INSULET CORP's most recent earnings 8-K?
INSULET CORP's latest earnings 8-K (Item 2.02) was filed May 6, 2026 under accession 0001145197-26-000100. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View INSULET CORP's latest earnings 8-K →
Look up any company's CIK number →